Fingolimod Immune Effects Beyond Its Sequestration Ability
Open Access
- 6 November 2019
- journal article
- review article
- Published by Springer Science and Business Media LLC in Neurology and Therapy
- Vol. 8 (2), 231-240
- https://doi.org/10.1007/s40120-019-00162-7
Abstract
Fingolimod is the first orally administered drug approved for the treatment of relapsing–remitting multiple sclerosis (MS). This drug, modulating sphingosine receptors, regulates the trafficking of lymphocytes between primary and secondary lymphoid organs, trapping naïve T cells and central memory T cells in secondary lymphoid organs, without affecting effector memory T cells and therefore without compromising immunosurveillance. Additionally, fingolimod inhibits expression of Th1 and Th17 cytokines and enhances regulatory T-cell differentiation. It also acts on the B arm of immunity through an increased ratio of naïve to memory B cells, higher percentage of plasma cells, and highly increased proportion of transitional B cells as well as additional regulatory subsets. Fingolimod treatment enhances the capacity of regulatory B cells to transmigrate across brain endothelial cells. In fact, patients treated with fingolimod have increased regulatory B-cell frequency in the cerebrospinal fluid. These findings suggest a novel role for fingolimod in MS, by both direct effects and indirect partitioning effects on lymphocytes.Keywords
This publication has 55 references indexed in Scilit:
- Consistent control of disease activity with fingolimod versus IFN β-1a in paediatric-onset multiple sclerosis: further insights from PARADIGMSJournal of Neurology, Neurosurgery & Psychiatry, 2019
- Fingolimod therapy modulates circulating B cell composition, increases B regulatory subsets and production of IL-10 and TGFβ in patients with Multiple SclerosisJournal of Autoimmunity, 2016
- Fingolimod does not impair T-cell release from the thymus and beneficially affects Treg function in patients with multiple sclerosisMultiple Sclerosis Journal, 2015
- From the regulatory functions of B cells to the identification of cytokine-producing plasma cell subsetsCurrent Opinion in Immunology, 2014
- Suppressed pro-inflammatory properties of circulating B cells in patients with multiple sclerosis treated with fingolimod, based on altered proportions of B-cell subpopulationsClinical Immunology, 2014
- Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosisBrain, 2011
- Mechanism of Action of Oral Fingolimod (FTY720) in Multiple SclerosisClinical Neuropharmacology, 2010
- Oligoclonal myelin-reactive T-cell infiltrates derived from multiple sclerosis lesions are enriched in Th17 cellsClinical Immunology, 2009
- Characterizing the Mechanisms of Progression in Multiple SclerosisArchives of Neurology, 2005
- Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosisNature Medicine, 2005